108 related articles for article (PubMed ID: 20549338)
1. Adjuvant chemotherapy is not for everyone.
Henderson IC
Breast Cancer Res Treat; 2010 Aug; 123(1):159-62. PubMed ID: 20549338
[No Abstract] [Full Text] [Related]
2. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
Park YH; Kim ST; Cho EY; Choi YL; Ok ON; Baek HJ; Lee JE; Nam SJ; Yang JH; Park W; Choi DH; Huh SJ; Ahn JS; Im YH
Breast Cancer Res Treat; 2010 Feb; 119(3):653-61. PubMed ID: 19957028
[TBL] [Abstract][Full Text] [Related]
3. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
5. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
Bao G; Yang DQ; Zhou B; Liu P; Wang S; Cheng L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2843-5. PubMed ID: 18167290
[TBL] [Abstract][Full Text] [Related]
6. Coming of age: breast cancer in seniors.
Muss HB
Oncologist; 2011; 16 Suppl 1():79-87. PubMed ID: 21278444
[TBL] [Abstract][Full Text] [Related]
7. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy of triple negative breast cancer.
Perez EA; Moreno-Aspitia A; Aubrey Thompson E; Andorfer CA
Breast Cancer Res Treat; 2010 Apr; 120(2):285-91. PubMed ID: 20094772
[TBL] [Abstract][Full Text] [Related]
9. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
Zhao J; Wu YL; Wang YD; Zhao GR; Wang J
Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1437-9. PubMed ID: 15604081
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Perez EA; Patel T; Moreno-Aspitia A
Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
[TBL] [Abstract][Full Text] [Related]
11. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.
Yu KD; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2009 Dec; 118(3):661-3. PubMed ID: 19714461
[No Abstract] [Full Text] [Related]
12. Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?
Chiuri VE; Lorusso V
Oncology; 2009; 77 Suppl 1():18-22. PubMed ID: 20130428
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
14. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
Ellis MJ
J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793
[No Abstract] [Full Text] [Related]
15. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
Montemurro F; Aglietta M
Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
[TBL] [Abstract][Full Text] [Related]
16. [The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma].
Wang S; Zhang JQ; Qiao XM; Yang DQ; Tong FZ; Liu HJ
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):1011-3. PubMed ID: 16194363
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab: new indication. Adjuvant breast cancer treatment for a minority.
Prescrire Int; 2007 Jun; 16(89):106. PubMed ID: 17582927
[TBL] [Abstract][Full Text] [Related]
18. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy for early-stage breast cancer.
McArthur HL; Hudis CA
Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
[TBL] [Abstract][Full Text] [Related]
20. A review of triple-negative breast cancer.
Ismail-Khan R; Bui MM
Cancer Control; 2010 Jul; 17(3):173-6. PubMed ID: 20664514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
